Important Happenings in HIV/Health Policy

Important Happenings in HIV/Health Policy

Week ending: April 12, 2019 By: Sable K. Nelson HIV Rates Are Rising Across the American South in States That Didn't Expand Medicaid Dramatically reducing HIV infections in the next decade will prove very difficult—and may be impossible with cuts to Medicaid or the repeal of the ACA. For more information, READ. Kaiser Family Foundation [...]
Important Happenings in HIV/Health Policy

Important Happenings in HIV/Health Policy

Week ending: April 5, 2019 By: Sable K. Nelson Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy for HIV Pre-Exposure Prophylaxis On April 5, 2019– Gilead Sciences, Inc. announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for […]

Important Happenings in HIV/Health Policy

Important Happenings in HIV/Health Policy

Important Happenings in HIV/Health Policy Week ending: March 15, 2019 By: Sable K. Nelson Trump Administration Releases its FY20 Budget Request Trump Administration Releases its FY20 Budget Request On March 11, 2019, the Trump Administration released its FY20 budget request to Congress, including top-line funding requests for federal HIV/AIDS programs (for more information: https://www.whitehouse.gov/wp-content/uploads/2019/03/budget-fy2020.pdf). The […]

Important Happenings in HIV/Health Policy

Important Happenings in HIV/Health Policy Week ending: March 8, 2019 By: Sable K. Nelson & Matthew Rose NOTE: President Trump released his FY20 budget request to Congress, including top-line funding requests for federal HIV/AIDS programs, on March 11. Supplemental information, including line item details for each agency, is expected to be released on March 18. […]

Important Happenings in HIV/Health Policy

Important Happenings in HIV/Health Policy Week ending: March 1, 2019 By: Sable K. Nelson & Matthew Rose Drug-Company Patents vs. the Public Good: Should the NIH Break This Medication Patent? Truvada, which is made by California-based Gilead Sciences, is the only drug approved by the FDA for pre-exposure prophylaxis, or PrEP, a course of treatment […]

Important Happenings in HIV/Health Policy

Important Happenings in HIV/Health Policy Week ending: February 22, 2018 By: Sable K. Nelson & Matthew Rose JAIDS: Clinical outcomes of young black men receiving HIV medical care in the United States, 2009–2014 More than one-quarter of 2016 HIV diagnoses among blacks in the U.S. occurred among persons aged 15–24 years, and three-quarters were among […]